Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.51 USD
+0.01 (0.40%)
Updated Jun 3, 2024 04:00 PM ET
Pre-Market: $2.49 -0.02 (-0.80%) 9:18 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 201 - 215 ( 215 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 - Allogene Continues to Aim for Excellence in ALLO CAR-T Delivery
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rafael Amado Joins Allogene as Chief Medical Officer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy 2.0: Moving Beyond CAR-Ts in Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Round 2 May Supersede Round 1 and It''s Priced In. Initiating at Neutral.
Provider: Roth Capital Partners, Inc.